Sculptor Capital LP raised its stake in Haleon PLC Sponsored ADR (NYSE:HLN – Free Report) by 5.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,454,868 shares of the company’s stock after acquiring an additional 505,000 shares during the quarter. Haleon makes up 1.1% of Sculptor Capital LP’s portfolio, making the stock its 19th biggest holding. Sculptor Capital LP owned approximately 0.23% of Haleon worth $105,699,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently made changes to their positions in the company. Parkside Financial Bank & Trust raised its holdings in shares of Haleon by 101.3% in the fourth quarter. Parkside Financial Bank & Trust now owns 2,847 shares of the company’s stock worth $29,000 after acquiring an additional 1,433 shares during the last quarter. Stance Capital LLC acquired a new position in shares of Haleon in the third quarter worth $34,000. Geneos Wealth Management Inc. raised its holdings in shares of Haleon by 33.0% in the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after acquiring an additional 1,203 shares during the last quarter. Assetmark Inc. raised its holdings in shares of Haleon by 26.6% in the fourth quarter. Assetmark Inc. now owns 5,962 shares of the company’s stock worth $60,000 after acquiring an additional 1,252 shares during the last quarter. Finally, Atlantic Union Bankshares Corp raised its holdings in shares of Haleon by 69.4% in the fourth quarter. Atlantic Union Bankshares Corp now owns 6,264 shares of the company’s stock worth $63,000 after acquiring an additional 2,567 shares during the last quarter. 6.67% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on the company. Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Argus raised Haleon to a “strong-buy” rating in a report on Tuesday, March 17th. Finally, Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a report on Thursday, April 30th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Haleon presently has an average rating of “Moderate Buy”.
Haleon Stock Performance
Haleon stock opened at $9.08 on Tuesday. The firm has a market capitalization of $40.14 billion, a P/E ratio of 23.27, a PEG ratio of 2.08 and a beta of 0.13. The stock has a fifty day moving average price of $9.33 and a 200 day moving average price of $9.90. Haleon PLC Sponsored ADR has a 52 week low of $8.65 and a 52 week high of $11.28. The company has a current ratio of 0.92, a quick ratio of 0.71 and a debt-to-equity ratio of 0.47.
Haleon (NYSE:HLN – Get Free Report) last released its earnings results on Saturday, February 14th. The company reported $6.32 EPS for the quarter. The business had revenue of $3.65 billion during the quarter. Equities research analysts anticipate that Haleon PLC Sponsored ADR will post 0.56 earnings per share for the current year.
About Haleon
Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.
The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.
Featured Stories
- Five stocks we like better than Haleon
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Want to see what other hedge funds are holding HLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haleon PLC Sponsored ADR (NYSE:HLN – Free Report).
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.
-etf-logo-1200x675.png){kind=logo}
